| Literature DB >> 23945236 |
Jae-Hyuck Shim1, Matthew B Greenblatt, Weiguo Zou, Zhiwei Huang, Marc N Wein, Nicholas Brady, Dorothy Hu, Jean Charron, Heather R Brodkin, Gregory A Petsko, Dennis Zaller, Bo Zhai, Steven Gygi, Laurie H Glimcher, Dallas C Jones.
Abstract
Mice deficient in Schnurri-3 (SHN3; also known as HIVEP3) display increased bone formation, but harnessing this observation for therapeutic benefit requires an improved understanding of how SHN3 functions in osteoblasts. Here we identified SHN3 as a dampener of ERK activity that functions in part downstream of WNT signaling in osteoblasts. A D-domain motif within SHN3 mediated the interaction with and inhibition of ERK activity and osteoblast differentiation, and knockin of a mutation in Shn3 that abolishes this interaction resulted in aberrant ERK activation and consequent osteoblast hyperactivity in vivo. Additionally, in vivo genetic interaction studies demonstrated that crossing to Lrp5(-/-) mice partially rescued the osteosclerotic phenotype of Shn3(-/-) mice; mechanistically, this corresponded to the ability of SHN3 to inhibit ERK-mediated suppression of GSK3β. Inducible knockdown of Shn3 in adult mice resulted in a high-bone mass phenotype, providing evidence that transient blockade of these pathways in adults holds promise as a therapy for osteoporosis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23945236 PMCID: PMC3754267 DOI: 10.1172/JCI69443
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808